Donor | 0 μM2-a | 2 μM | 10 μM | 20 μM | 50 μM |
---|---|---|---|---|---|
HL-N095 | 3.312-b | 8.35 | 9.57 | 11.17 | N.D. |
HL-N098 | 5.41 | 10.67 | 8.24 | 9.63 | N.D. |
HL-N100 | 3.19 | 8.77 | 8.13 | 8.90 | N.D. |
H232 | 1.89 | N.D. | N.D. | N.D. | 8.01 |
H233 | 3.36 | 8.09 | 12.24 | 7.64 | 11.38 |
H249 | 1.84 | 7.78 | 7.66 | 6.96 | 7.48 |
H254 | 0.64 | 3.39 | 3.82 | 6.32 | 3.98 |
N.D., not determined.
↵2-a Final concentrations of rifampin in primary cultures of human hepatocytes.
↵2-b Human hepatocytes were treated with rifampin for 3 days. Microsomes were prepared 24 hr after the last treatment, and the CYP3A4 activity was determined by measuring testosterone 6β-hydroxylase activity (nmol/mg/min) as described previously (Pearce et al., 1996).